Form 4: Adaptive Biotechnologies Director Acquires Shares and Options

Michael J Pellini, a director of Adaptive Biotechnologies, reported acquiring shares and stock options on March 4, 2025.

Summary

• On March 4, 2025, Michael J Pellini, a director of Adaptive Biotechnologies Corp, acquired 15,394 shares of common stock at $0.
• Following the transaction, Pellini directly owns 69,690 shares of common stock.
• Pellini also acquired 23,726 stock options with an exercise price of $8.12, vesting monthly over one year from March 4, 2025, and expiring on March 4, 2035.
• After the transaction, Pellini directly owns 23,726 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options by a director could be interpreted as a slightly positive signal, but it's not a strong indicator.

Positives

• A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the options suggests continued service as a director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from a company director.

Key Dates